Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc.'s SEC filings document financial results, operating updates, governance matters, and public-company disclosures for its beverage brand portfolio. Form 8-K reports include quarterly and annual results, guidance updates, Regulation FD disclosures, and other material events related to the company’s coconut water and better-for-you beverage operations.
Proxy materials describe annual meeting proposals, board structure, committee assignments, executive compensation, equity awards, and stockholder voting matters. Additional 8-K filings record director appointments, board retirements, officer roles, compensation arrangements, tariff-related disclosures, and the company’s capital-market reporting obligations as a Nasdaq-listed Delaware corporation.
Liran Ira reported acquisition or exercise transactions in this Form 4 filing.
Vita Coco Company, Inc. director Liran Ira reported a compensation-related stock grant rather than an open-market trade. He received 1,530 restricted stock units (RSUs) of common stock at a reference price of $75.18 per share under the company's 2021 Incentive Award Plan.
The RSUs vest in full on the earlier of the day immediately before the next annual stockholders meeting after the grant date or the first anniversary of the grant date, if he remains in continuous service. After this grant, Ira holds 479,871 shares directly and 572,579 shares indirectly through the Ira Liran 2012 Family Trust.
Vita Coco Company, Inc. director Jane Cecil Morreau received an equity grant of 1,530 shares of Common Stock on June 3, 2026, reported as deferred RSUs that will vest in full before the next annual stockholders meeting or on the first anniversary of the grant date, subject to continued board service. Following this grant, she directly holds 18,709 Common shares. She also holds a fully vested, currently exercisable non-qualified stock option covering 30,500 Common shares at an exercise price of $10.178 per share, expiring on July 12, 2031.
Vita Coco Company, Inc. director Kenneth Sadowsky reported a routine equity compensation grant. He received 1,530 shares of Common Stock as deferred restricted stock units (RSUs) that vest in full on the earlier of the day before the next Annual Stockholders Meeting after the grant date or the first anniversary of the grant date, as long as he remains in continuous service. These deferred RSUs will settle on June 3, 2031, with each unit delivering one share of common stock. After this grant, Sadowsky directly holds 584,196 shares of Common Stock. He also holds a fully vested, currently exercisable non-qualified stock option covering 27,300 shares of Common Stock at an exercise price of $10.178 per share, expiring on January 2, 2030.
Dozie Aishetu Fatima reported acquisition or exercise transactions in this Form 4 filing.
Vita Coco Company, Inc. director Dozie Aishetu Fatima reported receiving an award of 1,530 shares of common stock on 2026-06-03 as a compensation grant. The filing prices the grant at $75.18 per share. Following this award, she directly holds 16,376 shares of Vita Coco common stock.
According to the footnote, the grant represents deferred restricted stock units under the company’s 2021 Incentive Award Plan. These units vest in full on the earlier of the day immediately before the next Annual Stockholders Meeting after the grant date or the first anniversary of the grant date, provided she continues serving on the board. The deferred RSUs will settle in shares when she ceases service on the board, with each unit delivering one share of Vita Coco common stock.
Vita Coco Company, Inc. director John Zupo reported an equity compensation grant and his current holdings. He received 1,530 deferred restricted stock units (RSUs), each representing one share of common stock, granted under the company’s 2021 Incentive Award Plan. These RSUs vest in full on the earlier of the day immediately preceding the next Annual Stockholders Meeting after the grant date or the first anniversary of the grant date, provided he remains in continuous service, and will settle on June 3, 2031. Following this grant, he holds 13,692 shares of common stock directly. He also holds a fully vested, currently exercisable non-qualified stock option covering 20,675 shares of common stock at an exercise price of $10.178 per share, expiring on December 16, 2029.
Vita Coco Company, Inc. director Shelley G. Broader received a grant of 1,530 shares of common stock in the form of restricted stock units (RSUs) valued at $75.18 per share. After this equity award, her directly held common stock position reported in this filing is 2,050 shares.
The RSUs were granted under the company’s 2021 Incentive Award Plan and vest in full on the earlier of the day immediately before the next Annual Stockholders Meeting after the grant date or the first anniversary of the grant date, as long as she remains in continuous service. Each RSU converts into one share of Vita Coco common stock when it vests.
Vita Coco Company, Inc. director Eric Melloul received an equity grant of 1,530 shares of common stock in the form of restricted stock units (RSUs). The award was valued at $75.18 per share for reporting purposes and increased his direct holdings to 4,816 shares.
The RSUs were granted under the company’s 2021 Incentive Award Plan and will vest in full on the earlier of the day immediately preceding the next Annual Stockholders Meeting after the grant date or the first anniversary of the grant date, as long as he remains in continuous service. Each RSU converts into one share of common stock when it vests.
The Vita Coco Company, Inc. reported the results of its annual stockholder meeting held on June 3, 2026. Stockholders owning 50,426,796 shares of common stock were present or represented by proxy, representing approximately 88.49 percent of the voting power as of the April 7, 2026 record date.
Three Class II directors — Shelley Broader, Michael Kirban and Kenneth Sadowsky — were elected for terms expiring at the 2029 annual meeting. Each received substantially more votes "for" than "withheld," with several million broker non-votes recorded on the director proposals.
Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 50,014,018 votes for, 401,208 against and 11,570 abstentions. In addition, they approved the advisory vote on executive compensation with 44,532,948 votes for, 2,168,378 against, 31,044 abstentions and 3,694,426 broker non-votes.
Vita Coco Company, Inc. Chief Commercial Officer Charles van Es reported an open-market sale of 8,045 shares of common stock at $75.05 per share, executed under a Rule 10b5-1 trading plan. After this sale, he directly holds 59,085 common shares.
He also holds several non-qualified stock options to buy common stock, with exercise prices ranging from $10.178 to $33.36 per share and expiration dates from 2030 to 2035, reflecting a continuing equity-based position in the company.
COCO notices intended sales of Common Stock under Rule 144 by an affiliate and shows recent dispositions by a holder. The filing lists planned vesting entries on 08/15/2025 (3,762 shares) and 11/27/2025 (4,283 shares). Recent reported sales include $599,270 for 8,561 shares on 05/08/2026 and three smaller dispositions of 2,000 shares each on 03/16/2026, 04/01/2026 and 05/01/2026.